<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145222</url>
  </required_header>
  <id_info>
    <org_study_id>CNS 7056-004</org_study_id>
    <nct_id>NCT01145222</nct_id>
  </id_info>
  <brief_title>Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy</brief_title>
  <official_title>A Phase IIb Study Evaluating the Safety and Efficacy of Multiple Doses of CNS 7056 Compared to Midazolam in Patients Undergoing Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this dose-response study is to assess the safety and efficacy of CNS 7056
      compared with midazolam to maintain suitable sedation levels in patients undergoing
      colonoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, parallel group, dose-response study to assess the safety
      and efficacy of three dose levels of CNS 7056 compared with midazolam to maintain suitable
      sedation levels in patients undergoing colonoscopy.

      Safety assessment will include physical examinations, vital signs, ECGs, pulse oximetry
      measurements, capnography, clinical chemistry and hematology laboratory tests, routine drug
      and ethanol screening, urinalysis, pregnancy test, pain on injection using a verbal scale,
      and monitoring of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rates of the Procedure</measure>
    <time_frame>From start of study drug injection to patient discharge</time_frame>
    <description>Success of the procedure is a composite endpoint consisting of: Modified Observer's Assessment for Alertness/Sedation (MOAA/S) scores ≤4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure AND no requirement for rescue sedative medication AND no requirement for manual or mechanical ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Fully Alert</measure>
    <time_frame>From last injection of double-blind study medication until fully alert criteria are reached</time_frame>
    <description>Time to first of 3 consecutive MOAA/S scores of 5 after the last injection of double-blind study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ready for Discharge</measure>
    <time_frame>After the Last Injection of Double-Blind Study Medication AND after end of colonoscopy until first of 3 consecutive Aldrete scores ≥ 9</time_frame>
    <description>Time of the first of 3 consecutive Aldrete scores ≥ 9</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>A. Remimazolam (CNS 7056)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.
Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Remimazolam (CNS 7056)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance.
Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C. Remimazolam (CNS 7056)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.
Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D. Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance.
Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A. CNS 7056</intervention_name>
    <description>Initial low dose plus supplemental doses as necessary.</description>
    <arm_group_label>A. Remimazolam (CNS 7056)</arm_group_label>
    <other_name>CAS No. 1001415-66-2</other_name>
    <other_name>Remimazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B. CNS 7056</intervention_name>
    <description>Initial intermediate dose plus supplemental doses as necessary.</description>
    <arm_group_label>B. Remimazolam (CNS 7056)</arm_group_label>
    <other_name>CAS No. 1001415-66-2</other_name>
    <other_name>Remimazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C. CNS 7056</intervention_name>
    <description>Initial high dose plus supplemental doses as necessary.</description>
    <arm_group_label>C. Remimazolam (CNS 7056)</arm_group_label>
    <other_name>CAS No. 1001415-66-2</other_name>
    <other_name>Remimazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D. Midazolam</intervention_name>
    <description>Initial standardized dose plus supplemental doses as necessary.</description>
    <arm_group_label>D. Midazolam</arm_group_label>
    <other_name>CAS No. 59467-96-8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients, aged 18 to 70 years inclusive, scheduled to undergo a
             standard colonoscopy.

          -  American Society of Anesthesiologists Physical Status (ASA PS) Score I, II, or III.

          -  Weight range 55 to 130 kg inclusive.

          -  Body mass index (BMI) range 18 to 33 kg/m2 inclusive

          -  Patients of child-bearing potential and their partners must have been willing to use
             adequate contraception such as an intrauterine device, diaphragm or condom during the
             study and until 1 month after the last study drug administration. Childbearing
             potential was defined as &quot;all patients unless they were a female post menopausal for
             at least 2 years, or were surgically sterile.&quot;

          -  Patient voluntarily signed and dated an ICF that was approved by an IRB prior to the
             conduct of any study procedure.

          -  Patient was willing and able to comply with study requirements and return for a Follow
             up Visit (Day 4 ± 3 day) after the colonoscopy.

        Exclusion Criteria:

          -  Expected duration of colonoscopy &gt; 30 minutes.

          -  Patients with a suspected or diagnosed pathology of the lower GI tract that would have
             added to the risk of colonoscopy, such as strictures, active inflammatory bowel
             disease.

          -  ASA III patients with history of sleep apnea.

          -  ASA III patients with obesity (BMI ≥ 30 kg/m2).

          -  Patients with evidence of uncontrolled renal, hepatic, central nervous system,
             respiratory, cardiovascular or metabolic dysfunction, or other clinically significant
             (CS) findings at screening that, in the investigator's or medical monitor's opinion,
             should have excluded them from the study.

          -  Patients with clinically significant abnormalities in 12 lead ECG recorded at
             screening.

          -  Female patients with a positive serum human chorionic gonadotropin (HCG) pregnancy
             test at screening or baseline.

          -  Lactating female patients.

          -  Patients with positive drugs of abuse screen at baseline.

          -  Patients with positive serum ethanol at baseline.

          -  Patient with a history of drug or ethanol abuse.

          -  Patients in receipt of any investigational drug within 30 days or less than 7 half
             lives (whichever was longer) before the start of the study, or scheduled to receive
             one during the study period.

          -  Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone,
             or a medical condition such that these agents were contraindicated.

          -  Patients with an inability to communicate well with the investigator.

          -  Patients in whom management of airway was judged to be difficult due to, e.g.,
             thyro-mental distance ≤ 4 cm (&quot;short neck&quot;), or Mallampati score of 4.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACRI Phase I LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Associates</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pambianco DJ, Borkett KM, Riff DS, Winkle PJ, Schwartz HI, Melson TI, Wilhelm-Ogunbiyi K. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2016 May;83(5):984-92. doi: 10.1016/j.gie.2015.08.062. Epub 2015 Sep 9.</citation>
    <PMID>26363333</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>June 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2010</study_first_posted>
  <results_first_submitted>December 14, 2018</results_first_submitted>
  <results_first_submitted_qc>December 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 8, 2019</results_first_posted>
  <disposition_first_submitted>August 4, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 4, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 15, 2011</disposition_first_posted>
  <last_update_submitted>December 14, 2018</last_update_submitted>
  <last_update_submitted_qc>December 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNS 7056</keyword>
  <keyword>Procedural Sedation</keyword>
  <keyword>Colonoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Remimazolam 8.0/3.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 8 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="P2">
          <title>Remimazolam 7.0/2.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 7 mg for sedation induction, and 2 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="P3">
          <title>Remimazolam 5.0/3.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="P4">
          <title>Midazolam 2.5/1.0</title>
          <description>Double-blind Midazolam iv arm: 2.5 mg for sedation induction, and 1.0 mg top-ups for sedation maintenance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention to Treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Procedure not done (no anesthesiologist)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor bowel preparation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Analysis Population is the Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Remimazolam 8.0/3.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 8 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="B2">
          <title>Remimazolam 7.0/2.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 7 mg for sedation induction, and 2 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="B3">
          <title>Remimazolam 5.0/3.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="B4">
          <title>Midazolam 2.5/1.0</title>
          <description>Double-blind Midazolam iv arm: 2.5 mg for sedation induction, and 1 mg top-ups for sedation maintenance.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="11.22"/>
                    <measurement group_id="B2" value="54.5" spread="8.07"/>
                    <measurement group_id="B3" value="54.0" spread="10.30"/>
                    <measurement group_id="B4" value="55.5" spread="5.86"/>
                    <measurement group_id="B5" value="54.6" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.15" spread="11.0"/>
                    <measurement group_id="B2" value="168.18" spread="8.3"/>
                    <measurement group_id="B3" value="169.01" spread="11.3"/>
                    <measurement group_id="B4" value="169.87" spread="10.1"/>
                    <measurement group_id="B5" value="169.06" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.68" spread="13.4"/>
                    <measurement group_id="B2" value="76.23" spread="11.6"/>
                    <measurement group_id="B3" value="76.79" spread="14.5"/>
                    <measurement group_id="B4" value="76.95" spread="13.6"/>
                    <measurement group_id="B5" value="77.41" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.79" spread="3.451"/>
                    <measurement group_id="B2" value="27.02" spread="4.042"/>
                    <measurement group_id="B3" value="26.73" spread="3.063"/>
                    <measurement group_id="B4" value="26.58" spread="3.515"/>
                    <measurement group_id="B5" value="27.03" spread="3.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rates of the Procedure</title>
        <description>Success of the procedure is a composite endpoint consisting of: Modified Observer's Assessment for Alertness/Sedation (MOAA/S) scores ≤4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure AND no requirement for rescue sedative medication AND no requirement for manual or mechanical ventilation</description>
        <time_frame>From start of study drug injection to patient discharge</time_frame>
        <population>Analysis Population is the ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam 8.0/3.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 8 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O2">
            <title>Remimazolam 7.0/2.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 7 mg for sedation induction, and 2 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O3">
            <title>Remimazolam 5.0/3.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O4">
            <title>Midazolam 2.5/1.0</title>
            <description>Double-blind Midazolam iv arm: 2.5 mg for sedation induction, and 1 mg top-ups for sedation maintenance.</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rates of the Procedure</title>
          <description>Success of the procedure is a composite endpoint consisting of: Modified Observer's Assessment for Alertness/Sedation (MOAA/S) scores ≤4 on three consecutive measurements after administration of study drug AND completion of the endoscopy procedure AND no requirement for rescue sedative medication AND no requirement for manual or mechanical ventilation</description>
          <population>Analysis Population is the ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Overall comparison between remimazolam and midazolam</non_inferiority_desc>
            <p_value>0.007</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fully Alert</title>
        <description>Time to first of 3 consecutive MOAA/S scores of 5 after the last injection of double-blind study medication</description>
        <time_frame>From last injection of double-blind study medication until fully alert criteria are reached</time_frame>
        <population>Analysis Population is the ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam 8.0/3.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 8 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O2">
            <title>Remimazolam 7.0/2.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 7 mg for sedation induction, and 2 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O3">
            <title>Remimazolam 5.0/3.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O4">
            <title>Midazolam 2.5/1.0</title>
            <description>Double-blind Midazolam iv arm: 2.5 mg for sedation induction, and 1 mg top-ups for sedation maintenance.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fully Alert</title>
          <description>Time to first of 3 consecutive MOAA/S scores of 5 after the last injection of double-blind study medication</description>
          <population>Analysis Population is the ITT Population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="7.48"/>
                    <measurement group_id="O2" value="11.3" spread="5.69"/>
                    <measurement group_id="O3" value="13.3" spread="7.21"/>
                    <measurement group_id="O4" value="15.2" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ready for Discharge</title>
        <description>Time of the first of 3 consecutive Aldrete scores ≥ 9</description>
        <time_frame>After the Last Injection of Double-Blind Study Medication AND after end of colonoscopy until first of 3 consecutive Aldrete scores ≥ 9</time_frame>
        <population>Analysis Population is the ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam 8.0/3.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 8 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O2">
            <title>Remimazolam 7.0/2.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 7 mg for sedation induction, and 2 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O3">
            <title>Remimazolam 5.0/3.0 mg</title>
            <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
          </group>
          <group group_id="O4">
            <title>Midazolam 2.5/1.0</title>
            <description>Double-blind Midazolam iv arm: 2.5 mg for sedation induction, and 1 mg top-ups for sedation maintenance.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ready for Discharge</title>
          <description>Time of the first of 3 consecutive Aldrete scores ≥ 9</description>
          <population>Analysis Population is the ITT Population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After last injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="8.52"/>
                    <measurement group_id="O2" value="12.4" spread="6.72"/>
                    <measurement group_id="O3" value="11.3" spread="4.86"/>
                    <measurement group_id="O4" value="15.3" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After end of colonoscopy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="6.29"/>
                    <measurement group_id="O2" value="4.6" spread="4.58"/>
                    <measurement group_id="O3" value="3.8" spread="4.16"/>
                    <measurement group_id="O4" value="5.5" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent Adverse Events (TEAEs) were collected from first dose of study drug until Day 4 ± 3 days, and were followed until resolution of any ongoing TEAE up to 30 days</time_frame>
      <desc>Total number of participants affected with Other (Not Including Serious) Adverse Events represents overall number of participants with non-serious TEAEs reported with a threshold of 5% in any of the arms</desc>
      <group_list>
        <group group_id="E1">
          <title>Remimazolam 8.0/3.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 8 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="E2">
          <title>Remimazolam 7.0/2.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 7 mg for sedation induction, and 2 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="E3">
          <title>Remimazolam 5.0/3.0 mg</title>
          <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 3 mg top-ups for sedation maintenance</description>
        </group>
        <group group_id="E4">
          <title>Midazolam 2.5/1.0</title>
          <description>Double-blind Midazolam iv arm: 2.5 mg for sedation induction, and 1 mg top-ups for sedation maintenance.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least 60 days prior to submission for publication, presentation or use, sponsor shall review and comment any proposed oral or written publication, which period may be extended for an additional 30 days. To seek patent protection, sponsor shall have the right to delay the proposed publication for an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Information</name_or_title>
      <organization>PAION UK Ltd</organization>
      <email>reg_paion@paion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

